Bee venom allergy vaccine - Allergopharma
Latest Information Update: 13 Aug 2015
At a glance
- Originator Allergopharma
- Class Antiallergics; Hymenoptera allergy immunotherapies; Immunotherapies; Venoms
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Bee venom hypersensitivity
Most Recent Events
- 13 Aug 2015 No recent reports on development identified - Phase-III for Bee venom hypersensitivity (Prevention) in Germany (unspecified route)